The Medical Letter on Drugs and Therapeutics
Glycopyrrolate/Formoterol (Bevespi Aerosphere) for COPD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Glycopyrrolate/Formoterol (Bevespi Aerosphere) for COPD
The FDA has approved a fixed-dose combination of the long-acting anticholinergic glycopyrrolate and the long-acting beta2-adrenergic agonist (LABA) formoterol (Bevespi Aerosphere – AstraZeneca) for long-term maintenance treatment of patients...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Glycopyrrolate/Formoterol (Bevespi Aerosphere) for COPD
Article code: 1505b
 Electronic, downloadable article - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.